Heterologous redox partners supporting the efficient catalysis of epothilone B biosynthesis by EpoK in Schlegelella brevitalea.
Electron transport partner
EpoK (CYP167A1)
Epothilone B
Gene overexpression
Whole-cell biotransformation
Journal
Microbial cell factories
ISSN: 1475-2859
Titre abrégé: Microb Cell Fact
Pays: England
ID NLM: 101139812
Informations de publication
Date de publication:
15 Sep 2020
15 Sep 2020
Historique:
received:
05
06
2020
accepted:
10
09
2020
entrez:
16
9
2020
pubmed:
17
9
2020
medline:
5
6
2021
Statut:
epublish
Résumé
Epothilone B is a natural product that stabilizes microtubules, similar to paclitaxel (Taxol); therefore, epothilone B and several derivatives have shown obvious antitumour activities. Some of these products are in clinical trials, and one (ixabepilone, BMS) is already on the market, having been approved by the FDA in 2007. The terminal step in epothilone B biosynthesis is catalysed by the cytochrome P450 enzyme EpoK (CYP167A1), which catalyses the epoxidation of the C12-C13 double bond (in epothilone C and D) to form epothilone A and B, respectively. Although redox partners from different sources support the catalytic activity of EpoK in vitro, the conversion rates are low, and these redox partners are not applied to produce epothilone B in heterologous hosts. Schlegelella brevitalea DSM 7029 contains electron transport partners that efficiently support the catalytic activity of EpoK. We screened and identified one ferredoxin, Fdx_0135, by overexpressing putative ferredoxin genes in vivo and identified two ferredoxin reductases, FdR_0130 and FdR_7100, by whole-cell biotransformation of epothilone C to effectively support the catalytic activity of EpoK. In addition, we obtained strain H7029-3, with a high epothilone B yield and found that the proportion of epothilone A + B produced by this strain was 90.93%. Moreover, the whole-cell bioconversion strain 7029-10 was obtained; this strain exhibited an epothilone C conversion rate of 100% in 12 h. Further RT-qPCR experiments were performed to analyse the overexpression levels of the target genes. Gene knock-out experiments showed that the selected ferredoxin (Fdx_0135) and its reductases (FdR_0130 and FdR_7100) might participate in critical physiological processes in DSM 7029. Gene overexpression and whole-cell biotransformation were effective methods for identifying the electron transport partners of the P450 enzyme EpoK. In addition, we obtained an epothilone B high-yield strain and developed a robust whole-cell biotransformation system. This strain and system hold promise for the industrial production of epothilone B and its derivatives.
Sections du résumé
BACKGROUND
BACKGROUND
Epothilone B is a natural product that stabilizes microtubules, similar to paclitaxel (Taxol); therefore, epothilone B and several derivatives have shown obvious antitumour activities. Some of these products are in clinical trials, and one (ixabepilone, BMS) is already on the market, having been approved by the FDA in 2007. The terminal step in epothilone B biosynthesis is catalysed by the cytochrome P450 enzyme EpoK (CYP167A1), which catalyses the epoxidation of the C12-C13 double bond (in epothilone C and D) to form epothilone A and B, respectively. Although redox partners from different sources support the catalytic activity of EpoK in vitro, the conversion rates are low, and these redox partners are not applied to produce epothilone B in heterologous hosts.
RESULTS
RESULTS
Schlegelella brevitalea DSM 7029 contains electron transport partners that efficiently support the catalytic activity of EpoK. We screened and identified one ferredoxin, Fdx_0135, by overexpressing putative ferredoxin genes in vivo and identified two ferredoxin reductases, FdR_0130 and FdR_7100, by whole-cell biotransformation of epothilone C to effectively support the catalytic activity of EpoK. In addition, we obtained strain H7029-3, with a high epothilone B yield and found that the proportion of epothilone A + B produced by this strain was 90.93%. Moreover, the whole-cell bioconversion strain 7029-10 was obtained; this strain exhibited an epothilone C conversion rate of 100% in 12 h. Further RT-qPCR experiments were performed to analyse the overexpression levels of the target genes. Gene knock-out experiments showed that the selected ferredoxin (Fdx_0135) and its reductases (FdR_0130 and FdR_7100) might participate in critical physiological processes in DSM 7029.
CONCLUSION
CONCLUSIONS
Gene overexpression and whole-cell biotransformation were effective methods for identifying the electron transport partners of the P450 enzyme EpoK. In addition, we obtained an epothilone B high-yield strain and developed a robust whole-cell biotransformation system. This strain and system hold promise for the industrial production of epothilone B and its derivatives.
Identifiants
pubmed: 32933531
doi: 10.1186/s12934-020-01439-5
pii: 10.1186/s12934-020-01439-5
pmc: PMC7493146
doi:
Substances chimiques
Bacterial Proteins
0
Epothilones
0
Ferredoxins
0
epothilone C
18T00XLN7E
epothilone A
51E07YBX96
Cytochrome P-450 Enzyme System
9035-51-2
epothilone B
UEC0H0URSE
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
180Subventions
Organisme : National Key R&D Program of China
ID : 2018YFC0310600
Organisme : Basic Research Project of Science and Technology Commission of Shanghai Municipality
ID : 17JC1401800
Organisme : National Natural Science Foundation of China
ID : 31970049
Organisme : National Natural Science Foundation of China
ID : 31670098
Organisme : National Natural Science Foundation of China
ID : 31670097
Références
Biochim Biophys Acta. 2007 Mar;1770(3):330-44
pubmed: 16978787
Front Cell Neurosci. 2018 Sep 28;12:324
pubmed: 30323743
Eur J Med Chem. 2018 Sep 5;157:925-934
pubmed: 30149324
Acta Biochim Biophys Sin (Shanghai). 2019 Jul 10;51(7):697-706
pubmed: 31187113
Gene. 2000 May 16;249(1-2):153-60
pubmed: 10831849
World J Microbiol Biotechnol. 2017 Jul;33(7):137
pubmed: 28585173
ACS Chem Biol. 2017 Jul 21;12(7):1805-1812
pubmed: 28467833
Nucleic Acids Res. 2008 Oct;36(17):e113
pubmed: 18701643
Biochemistry. 2016 Dec 27;55(51):7047-7064
pubmed: 27966889
Biochemistry. 2006 Jan 31;45(4):1321-30
pubmed: 16430229
Appl Microbiol Biotechnol. 2008 Nov;81(1):109-17
pubmed: 18769916
J Biol Chem. 2003 Nov 7;278(45):44886-93
pubmed: 12933799
Science. 2000 Jan 28;287(5453):640-2
pubmed: 10649995
Appl Environ Microbiol. 2015 Sep;81(18):6268-75
pubmed: 26150455
Front Cell Neurosci. 2018 Aug 08;12:226
pubmed: 30135644
Sci Rep. 2018 Feb 8;8(1):2647
pubmed: 29422528
J Med Chem. 2012 Nov 8;55(21):8979-96
pubmed: 23020671
ACS Synth Biol. 2020 Aug 21;9(8):2009-2022
pubmed: 32603592
Biochim Biophys Acta Proteins Proteom. 2018 May 28;1866(9):933-940
pubmed: 29852252
Sci Rep. 2015 Oct 08;5:14881
pubmed: 26445909
Chem Biol. 2000 Feb;7(2):97-109
pubmed: 10662695
Int J Syst Evol Microbiol. 2019 Sep;69(9):2877-2883
pubmed: 31274403
Science. 2015 Apr 17;348(6232):347-52
pubmed: 25765066
Antimicrob Agents Chemother. 2002 Sep;46(9):2772-8
pubmed: 12183227
J Clin Oncol. 2007 Nov 20;25(33):5210-7
pubmed: 17968020
Bioorg Med Chem. 2018 Nov 1;26(20):5578-5581
pubmed: 30318441
Chem Rev. 2004 Sep;104(9):3947-80
pubmed: 15352783